drugset / Trial / NCT00279890

Topical Agent for Treatment of Red Skin

NCT00279890 ↗

Phase 1 Completed 20 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelTreatment

Summary

SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety

Timeline

Start
2005-07
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SR-01 Unknown — Topical

Indications